Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Holding AU:CHM?
Track your performance easily
CHM Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week Range<AU$0.01 - AU$0.05
Previous CloseAU$0.01
Volume300.00K
Average Volume (3M)2.10M
Market Cap
AU$11.06M
Enterprise Value-AU$8.43M
Total Cash (Recent Filing)AU$18.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Feb 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume2,587,778
30 Day Avg. Volume2,095,578
Standard Deviation0.20
R-Squared0.19
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)21654.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Chimeric Therapeutics Ltd. News
PremiumCompany Announcements
Chimeric Therapeutics Amends Constitution: Key Investor Insights
PremiumCompany Announcements
Chimeric Therapeutics Appoints New CEO Amid Growth
PremiumCompany Announcements
Chimeric Therapeutics Announces Extraordinary General Meeting
PremiumCompany Announcements
Chimeric Therapeutics Advances Cancer Trials and Secures Funding
PremiumCompany Announcements
Chimeric Therapeutics Announces Capital Raise and Updates
PremiumCompany Announcements
Chimeric Therapeutics Advances AML Trial with CORE NK Therapy
PremiumCompany Announcements
Chimeric Therapeutics Lists New Shares on ASXPremiumCompany Announcements
Chimeric Therapeutics Ltd. Announces $5 Million Share OfferOptions Prices
Currently, No data available
---
Ownership Overview
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Feb 19, 2025 which is in 89 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Aug 30, 2024. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.017.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 995,140,800 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
---
Chimeric Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-65.51%
12-Months-Change
Fundamentals
Return on Equity
-308.21%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells.
---
Technical Analysis
Australian Clinical Labs Ltd
―
Race Oncology Ltd.
―
Radiopharm Theranostics Limited
―
---